Efficacy and safety of using a fixed-dose combination of azilsartan medoxomil and chlorthalidone in patients with diabetes mellitus
| Autor: | Juliya V. Zhernakova, Irina E. Chazova |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Системные гипертензии, Vol 17, Iss 4, Pp 68-73 (2021) |
| Druh dokumentu: | article |
| ISSN: | 2075-082X 2542-2189 2075082X |
| DOI: | 10.26442/2075082X.2020.4.200556 |
| Popis: | All resent international and national guidelines for the treatment of patients with arterial hypertension offer a unified approach to the prescription of antihypertensive therapy. The vast majority of patients, including those with diabetes mellitus, require combined drugs. Renin-angiotensin-aldosterone system blockers, calcium channel blockers or diuretics are recommended as first-line therapy. The requirements for diuretics which can be used in this category of patients are especially strong. If patients with diabetes mellitus need diuretics as part of their antihypertensive therapy, thiazide-like diuretics should be preferred. Edarbi Clo, which is a fixed-dose combination of angiotensin receptor blocker azilsartan medoxomil and thiazide-like diuretic chlorthalidone met all these requirements. Along with its strong antihypertensive effect, Edarbi Clo has a beneficial effect on metabolism parameters, inflammation parameters and prevents damage to target organs, which makes it possible to recommend it as a drug of choice in this category of patients. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|